For research use only. Not for use in humans.

Neihulizumab (Anti-PSGL1 / CD162)

Synonyms: ALTB-168 Cat.No.A2373 Purity:99%

Neihulizumab (Anti-PSGL1 / CD162) is a humanised, agonistic monoclonal antibody against P selectin glycoprotein ligand-1 (PSGL-1, SELPLG, CD162) with potential immunosuppressive activity. It can halt the progression of T-cell-mediated autoimmune diseases and acute graft-versus-host disease (GvHD). MW: 150 kD.

Quality Control

Batch: Purity: 99% Protein concentration: 10.965mg/ml Endotoxin Level: ＜1EU/mg

Specificity

Expand to Check More

1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description	Neihulizumab (Anti-PSGL1 / CD162) is a humanised, agonistic monoclonal antibody against P selectin glycoprotein ligand-1 (PSGL-1, SELPLG, CD162) with potential immunosuppressive activity. It can halt the progression of T-cell-mediated autoimmune diseases and acute graft-versus-host disease (GvHD). MW: 150 kD.

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

Product Details

CAS No.	2158362-38-8
Molecular Weight	150 kDa
Isotype	Human IgG4SP
Source	CHO
Purification	AKTA
Sterility	0.2 μM filtered
Formulation	100 mM Pro-Ac, 20mM Arg, pH5.0
Storage	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

^*Literature analysis of various clone (for this target) products available on the market shows that Sellecks selected clones are more frequently applied. (data until September 2024)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.